Instrument Inactif

Communiqués Atossa Genetics Inc Nasdaq

Actions

US04962H1005

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

17/06	Atossa Therapeutics s'apprête à rejoindre l'indice Russell 3000 mis à jour	MT
28/05	Atossa Therapeutics, Inc. annonce le soutien d'une étude clinique testant un nouveau modèle d'évaluation des risques de cancer du sein basé sur l'intelligence artificielle	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Atossa Set to Join Russell 3000 Index Effective June 28, 2024	18/06	AQ
Atossa Set to Join Russell 3000® Index Effective June 28, 2024	17/06	AQ
Atossa to Present at the Sidoti Small-Cap Investor Conference	05/06	AQ
Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model	28/05	AQ
Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial	15/05	AQ
Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update	13/05	AQ
Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines	07/05	AQ
Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen	29/04	AQ
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib in Women with ER+/HER2- Breast Cancer	16/04	AQ
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer	15/04	AQ
Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference	11/04	AQ
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen	09/04	AQ
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update	01/04	AQ
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved 'Expanded Access' Program for a U.S. Breast Cancer Patient	20/03	AQ
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient	19/03	AQ
Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements	18/03	AQ
Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors	12/03	AQ
Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting	06/03	AQ
Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study	22/02	AQ
Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial	08/02	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Atossa Genetics Inc Nasdaq

Actions

US04962H1005

Communiqués

Filtres